1334782-79-4

Basic information

• Product Name: (R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethanone
• CAS NO: 1334782-79-4
• Molecular Weight: 512.679
• Mol File: 1334782-79-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethanone(1334782-79-4)
• EPA Substance Registry System: (R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethanone(1334782-79-4)

Safety Data

• Hazardous Substances Data: 1334782-79-4(Hazardous Substances Data)

Usage

Uses

PF 5190457 is a potent, selective, and orally bioavailable ghrelin receptor inverse agonist.

Biochem/physiol Actions

PF-05190457 is an orally available, potent and selective ghrelin receptor inverse agonist. PF-05190457 potently increases insulin secretion in glucose-stimulated human islets.

Upstream product

• 1334784-85-8 ethyl (2-methylimidazo[2,1-b][1,3]thiazol-6-yl)acetate 
• 1334784-84-7 ethyl (2-methylimidazo[2,1-b][1,3]thiazol-6-yl)acetate hydrobromide 
• 214360-81-3 5-( 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-inden-1-one 
• 1334784-86-9 (2-methylimidazo[2,1-b][1,3]thiazol-6-yl)acetic acid hydrochloride 
• 896464-16-7 2,7-diaza-spiro[3.5]nonane-7-carboxylic acid tert-butyl ester 
• 1414782-20-9 tert-butyl 2-[(R)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonane-7-carboxylate 
• 1334785-06-6 tert-butyl 2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonane-7-carboxylate 
• 1314319-10-2 tert-butyl 2-[(1R)-5-bromo-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonane-7-carboxylate 
• 1312131-45-5 tert-butyl 4-(chloromethyl)-4-(hydroxymethyl)piperidine-1-carboxylate 
• 1314319-01-1 1-tert-butyl 4-methyl 4-(chloromethyl)piperidine-1,4-dicarboxylate 
• 1312131-48-8 tert-butyl 4-(chloromethyl)-4-formylpiperidine-1-carboxylate 
• 1334784-73-4 (1R)-1-azido-5-bromo-2,3-dihydro-1H-indene 
• 1270284-15-5 (1S)-5-bromo-2,3-dihydro-1H-inden-1-ol 
• 1228561-27-0 (1R)-5-bromo-2,3-dihydro-1H-inden-1-amine 

Relevant articles and documents

Rational Design, Synthesis, and Pharmacological Characterization of Novel Ghrelin Receptor Inverse Agonists as Potential Treatment against Obesity-Related Metabolic Diseases

A new chemotype of ghrelin inverse agonists was discovered through chimeric design based on molecular scaffolds known as growth-hormone secretagogue receptor (GHSR) modulators but with divergent pharmacodynamic and pharmacokinetic properties. The structur

USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS

The present invention relates to methods of treating sleep disorders in patients comprising administration of a ghrelin receptor inverse agonist or antagonist. The invention also includes methods of treating sleep disorders comprising the administration of a pharmaceutical composition comprising a ghrelin receptor inverse agonist or antagonist and at least one pharmaceutically acceptable carrier, diluent, or excipient.